Loading…
Guangdong-based pharmaceutical manufacturer selling generic and specialty drugs in China.
Guangdong-based pharmaceutical manufacturer selling generic and specialty drugs in China.
Moat: none
Headquarters: Guangdong, China · Employees: 1,154
Size Guangdong Taienkang Pharmaceutical (301263.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.53B, the 1614th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥20.01 on 6 Nov 2026.
Performance Over six months the shares fell 16.8%, against -4.0% for the median peer and -16.4% for the China market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 1.8% over the last twelve months (peer median +6.2%); the operating margin is -2.1% (peer median 9.1%).
Valuation It trades at 42.9× forward earnings against a peer median of 25.9× (2nd most expensive of 11).
Capital Return on invested capital runs 6.6 points below its cost of capital (8.3% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥682M | CN¥670M | CN¥711M | CN¥755M | CN¥779M |
| Revenue growth | — | -6% | -6% | -3% | — |
| Gross profit | CN¥407M | CN¥325M | CN¥371M | CN¥430M | CN¥434M |
| EBITDA | n/a | CN¥67.2M | CN¥159M | CN¥219M | CN¥225M |
| Net income | CN¥28.7M | CN¥28.6M | CN¥108M | CN¥160M | CN¥175M |
| Free cash flow | -CN¥11.0M | -CN¥119M | CN¥25.3M | -CN¥97.9M | CN¥68.3M |
| Capital expenditure | CN¥140M | CN¥108M | CN¥68.6M | CN¥200M | CN¥89.9M |
| Total debt | CN¥617M | CN¥366M | CN¥247M | CN¥176M | CN¥23.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301263.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.1% | +0.3% | 8th highest of 21 |
| 6-month return | -16.8% | -4.0% | 7th lowest of 21 |
| Distance from 52-week high | -32.8% | -19.7% | 10th lowest of 21 |
| Revenue growth (TTM) | +1.8% | +6.2% | 8th lowest of 19 |
| Operating margin | -2.1% | 9.1% | 8th lowest of 19 |
| Forward P/E | 42.9× | 25.9× | 2nd most expensive of 11 |
| ROIC minus cost of capital | -6.6 pp | -0.4 pp | 7th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.53B | -17% | +2% | -2% | 42.9× | n/a | n/a |
| Ultragenyx Pharmaceutical RARE | United States | $1.52B | +22% | +16% | -64% | n/a | n/a | n/a |
| Nanobiotix NANO.PA | France | $1.54B | -42% | -77% | -392% | n/a | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.55B | +53% | -6% | -19% | n/a | 49.9% | -13.2% |
| Indegene INDGN.NS | India | $1.56B | +15% | +36% | 12% | 27.5× | 29.6% | +29.4% |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.49B | -17% | +1% | 19% | 13.0× | -8.5% | +4.6% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.56B | -5% | +4% | 9% | 18.5× | -5.8% | +1.9% |
| ABL Bio 298380.KS | South Korea | $1.49B | -73% | -64% | -251% | n/a | n/a | n/a |
| Corona Remedies CORONA.NS | India | $1.58B | +40% | +17% | 18% | 63.7× | 37.6% | +16.6% |
| Xiamen Kingdomway 002626.SZ | China | $1.58B | +15% | -3% | 11% | 30.0× | n/a | n/a |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.58B | -4% | +16% | 9% | 29.0× | n/a | n/a |
| LigaChem Biosciences 141080.KS | South Korea | $1.59B | -68% | -33% | -208% | n/a | n/a | n/a |
| Damora Therapeutics DMRA | United States | $1.46B | -2% | n/a | n/a | n/a | n/a | n/a |
| Marksans Pharma MARKSANS.NS | India | $1.45B | +50% | +24% | 20% | 24.2× | 31.6% | +16.6% |
| Pacira Biosciences PCRX | United States | $1.45B | +57% | +6% | 4% | 11.8× | 14.9% | +11.1% |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.45B | -48% | n/a | n/a | n/a | n/a | n/a |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.60B | -5% | +16% | 24% | n/a | -4.1% | +0.2% |
| Ocular Therapeutix OCUL | United States | $1.45B | -32% | -8% | -603% | n/a | n/a | n/a |
| Eton Pharmaceuticals ETON | United States | $1.61B | +236% | +81% | 16% | 27.9× | 39.6% | +359.6% |
| Mabwell (Shanghai) Bioscience 688062.SS | China | $1.44B | -38% | +15% | -129% | n/a | n/a | n/a |
| Mayinglong Pharmaceutical 600993.SS | China | $1.62B | -4% | +7% | 17% | 16.2× | -4.5% | +6.8% |